<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03941340</url>
  </required_header>
  <id_info>
    <org_study_id>20190130</org_study_id>
    <nct_id>NCT03941340</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Mass Balance And Biotransformation of Single Dose[14C] AST2818 in Chinese Healthy Male Volunteers</brief_title>
  <official_title>A Phase I Mass Balance and Biotransformation Study of Orally Administered [14C]-Alflutinib Mesylate (AST2818) in Chinese Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allist Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allist Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to Evaluate the Mass Balance and Biotransformation of Single Dose[14C] AST2818 in
      Chinese Healthy Male Volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I Mass Balance and Biotransformation Study of Orally Administered [14C]-Alflutinib
      Mesylate (AST2818) in Chinese Healthy Male Volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 8, 2019</start_date>
  <completion_date type="Actual">September 6, 2019</completion_date>
  <primary_completion_date type="Actual">September 6, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The distribution of AST2818 in the whole blood and plasma and whole radioactive pharmacokinetics following the single orally administered [14C]-AST2818 in healthy male volunteers.</measure>
    <time_frame>Blood samples (hrs) - 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, every 24 to 504, 672, 840, 1008, 1176, 1344, 1512, 1680, 1848 and 2016.</time_frame>
    <description>The percentage of radioactive dose of [14C] radiolabelled AST2818 recovered in blood and in total, up to Day 85（p.s:The administration time on the first day is 7:30 am）</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitive analysis of whole radioactivity of excrement of orally administered [14C]-AST2818 in healthy volunteers to obtain the mass balance data and the main excretion pathway in human body.</measure>
    <time_frame>Urine and faeces (hrs): 0-4, 4-8, 8-12, 12-24, every 24 to 504, 624-672, 792-840, 960-1008, 1128-1176, 1296-1344, 1464-1512, 1632-1680, 1800-1848 and 1968-2016.</time_frame>
    <description>The percentage of radioactive dose of [14C] radiolabelled AST2818 recovered in urine, faeces and in total, up to Day 85（p.s:The administration time on the first day is 7:30 am）</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitive analysis of the concentrations of AST2818 and AST5902 (Metabolite of AST2818) in plasma using the validated LC-MS/MS to obtain pharmacokinetic data;</measure>
    <time_frame>Blood samples (hrs) - 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, every 24 to 504, 672, 840, 1008, 1176, 1344, 1512, 1680, 1848 and 2016.</time_frame>
    <description>The concentrations of AST2818 and AST5902 in plasma up to Day 85（p.s:The administration time on the first day is 7:30 am）</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of different metabolites in healthy volunteers after oral administration of [14C]-AST2818</measure>
    <time_frame>Blood samples (hrs) - 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, every 24 to 504, 672, 840, 1008, 1176, 1344, 1512, 1680, 1848 and 2016.</time_frame>
    <description>Proportion of different metabolites</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Types of adverse events assessed by CTCAE v5.0 that occurred during the trial</measure>
    <time_frame>Baseline (Day-1) to Day 85（p.s:The administration time on the first day is 7:30 am）</time_frame>
    <description>Types of adverse events</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Male Volunteers</condition>
  <arm_group>
    <arm_group_label>[14C]-AST2818 80mg (oral solution)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive 80 mg [14C]-AST2818 containing a nominal 100 μCi activity, administered by mouth, as a solution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14]-AST2818</intervention_name>
    <description>Volunteer will receive a single oral dose of 80 mg /100 u Ci [14C]-AST2818 as a solution on Day 1</description>
    <arm_group_label>[14C]-AST2818 80mg (oral solution)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult;

          2. Body weight: The body mass index varies in the range of 19 - 26 kg/m2 (including 19
             and 26 kg/m2);

          3. Signing the informed consent forms by oneself ;

          4. Be able to communicate well with the researcher and be able to complete the trial in
             accordance with the program.

        Exclusion Criteria:

          1. Those with abnormal examination and clinical significance ( including Physical
             examination, routine laboratory examination (blood routine, urine routine, fecal
             routine + Occult blood, blood biochemistry, blood coagulation routine, thyroid
             function), 12-lead electrocardiogram, X-ray (positive position), abdominal B-mode
             ultrasonography (liver, gallbladder, pancreas, spleen and kidney), etc)；

          2. Those with routine urine examination showed positive urinary protein；

          3. Those with QTcF &gt; 470 msec in resting state, corrected by ECG during screening period；

          4. Those with HBsAg , HBeAg and HCVAb were positive；

          5. Those with HIVAb was positive；

          6. Those with treponema pallidum Ab was positive；

          7. Those who take any drugs that inhibit or induce the CYP450 enzyme (i.e., inducers-
             barbiturates, tegretol, phenytoin, rifampicin, hexadecadrol, rifabutin, rifapentini;
             inhibitors- SSRI-antidepressant, cimetidine, diltiazem, macrolides, verapamil,
             imidazoles- antifungal drugs) 30 days prior to screening period；

          8. Those who take any drug, health care products (including vitamins), chinese
             traditional medicine 14 days prior to screening period；

          9. Those who participated other clinical trials or took the investigational drug 3 months
             prior to screening period, or prepare to take part in other clinical trials within 1
             month after finishing this trial；

         10. Those who have history of organic heart disease, heart failure, myocardial infarction,
             angina, unexplained arrhythmia, torsional ventricular tachycardia, ventricular
             tachycardia and QT prolonged syndrome, or have the family history (Genetic proof or a
             close relative of sudden cardiac death at a young age) and symptom of QT prolonged
             syndrome ；

         11. Those who have severe disease of ophthalmic system, e.g., corneal, conjunctiva and
             eyelid diseases;

         12. Those who have undergone major surgery within the first 6 months of the screening
             period or have no complete surgical incision; major procedures include, but are not
             limited to, any operator with significant bleeding risk, prolonged general anesthesia,
             or incisional biopsy or significant traumatic injury;

         13. Those who have but not limited to circulatory system, endocrine system, nervous
             system, digestive system, urinary system, or have the history of blood, immunity
             spirit and metabolism diseases；

         14. Those who have allergic constitution, including being definitely allergic to TKIs or
             any ingredients of this trial drugs，any food materials or have special demands for
             foods，and cannot comply with the rule of unified diet；

         15. Those who have history of hand and foot syndrome；

         16. Those who have haemorrhoids or perianal disease with regular/ongoing hematochezia；

         17. Those who have coagulation dysfunction or other diseases of the blood system;

         18. Those who have history of tumor；

         19. Those who have habitual constipation or diarrhea, irritable bowel syndrome,
             inflammatory bowel disease；

         20. Those who have history of alcohol abuse (it was defined as that the daily alcohol
             consumption was higher than the following criteria: the weekly alcohol consumption was
             higher than 14 units of alcohol (1 unit= 360 ml beers/45 ml liquor containing 40%
             alcohol/150ml grape wine) 6 months prior to screening period, or the alcohol breath
             test results ≥20 mg/dl during screening period；

         21. Those who smoked daily &gt;5 sticks of cigarette 3 months prior to first dose or cannot
             give up smoking during study；

         22. Those have history of drug abuse or taking soft drug (i.e., marihuana) 3 months prior
             to screening period or taking hard drugs (i.e., cocaine, amphetamines, benzodiazepine,
             etc.); or the results of urine test in drugs were positive;

         23. Those who were used to drink grapefruit juice or overconsumption of tea, coffee, and
             the drink with caffeine; and cannot give up them during test；

         24. Those who need long-term exposure to radiation, or who have been exposed to
             significant radiation (&gt; 2 chest/abdominal CT scans or more than 3 other X-ray scans)
             or who have participated in the labeling test of radiopharmaceuticals within one year
             before the test;

         25. Those who have fertility planning within the range of starting trial - 1 year after
             finishing trial, or disagree with the regulation and their mate should take strict
             contraception (taking condoms, contraceptive sponges, contraceptive gels,
             contraceptive membranes, intrauterine devices, oral or injectable contraceptives and
             subcutaneous implants, etc.)；

         26. Those who have excessive bleeding or blood donation (400ml) 3 months prior to
             screening period, or planned to donate blood 1 month after finishing this trial；

         27. Those who cannot complete this study because of other reasons, or any factors judged
             by investigator that the participants cannot meet.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LiYan Miu</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 24, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>January 2, 2020</last_update_submitted>
  <last_update_submitted_qc>January 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

